? Career Development Program The purpose of the Mayo Clinic SPORE in Ovarian Cancer is to stimulate, organize and facilitate rigorous translational research that will meaningfully reduce the burden of ovarian cancer. A critical part of this process is to increase the quality and depth of the translational investigator base in ovarian cancer. During the first five years of funding, four individuals received Career Development Awards and were supported with 1-2 years of funding, mentoring teams, and full access to SPORE resources. Our awardees have been highly successful, with 14 manuscripts published and an additional 2 under review, all receiving subsequent funding and two (Paul Haluska and Matthew Block) advancing to co-leadership of projects in this renewal application; additionally, Dr. Haluska is the Director of the Animal Models Core. All awardees relied upon the Biospecimens and Biostatistics Cores to develop their research programs; Dr. Haluska also partnered with the Animal Models Core. The ultimate objectives of the Career Development Program (CDP) continue to be the identification and mentoring of new and developing investigators in ovarian cancer who demonstrate clear potential to become independent translational researchers as well as attracting established scientists who wish to refocus on ovarian cancer. The CDP provides up to $100,000 for one year of support ($50,000 from SPORE funds and a matching $50,000 from Mayo Clinic); a second year is possible based on progress and continued translational trajectory. Emphasis is placed on attracting highly qualified individuals underrepresented in medicine, including women and minorities. Identifying and selecting CDP awardees is accomplished through a rigorous review process, followed by intense mentoring, integration into ongoing SPORE activities and close oversight of the individual's progress. In addition to a primary mentor, awardees have complementary mentors in clinical, basic or population sciences necessary to ensure development of a translational research career. This capitalizes on numerous strengths present within the Mayo environment. The CDP reports to the Executive Committee of the Mayo Clinic Ovarian Cancer SPORE. During the next funding period, the Ovarian SPORE will continue to maintain: (1) a stringent candidate selection system; (2) comprehensive trainee guidance by a primary mentor; (3) support through a scientific mentoring group (the Individual Trainee Mentorship Committee) comprised of investigators with expertise in each trainee`s area of interest; and (4) full integration into the SPORE, including access to all scientific Cores. Mayo Clinic provides an exceptional environment for developing careers in translational research in ovarian cancer. The CDP allows us to identify, mentor, and support young investigators who will become future leaders in ovarian cancer research.

Public Health Relevance

The Career Development Program seeks to identify and mentor new and developing investigators in ovarian cancer. The SPORE assists these individuals by providing mentoring teams and actively integrating the awardee into the SPORE and providing access to Core resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA136393-08
Application #
9333239
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2009-09-01
Project End
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
8
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Zhang, Qing; Wang, Chen; Cliby, William A (2018) Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol Oncol :
Morehead, Lauren C; Cannon, Martin J (2018) Further clinical advancement of dendritic cell vaccination against ovarian cancer. Ann Res Hosp 2:
Botuyan, Maria Victoria; Cui, Gaofeng; Drané, Pascal et al. (2018) Mechanism of 53BP1 activity regulation by RNA-binding TIRR and a designer protein. Nat Struct Mol Biol 25:591-600
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Earp, Madalene; Tyrer, Jonathan P; Winham, Stacey J et al. (2018) Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS One 13:e0197561
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wu, Chenming; Luo, Kuntian; Zhao, Fei et al. (2018) USP20 positively regulates tumorigenesis and chemoresistance through ?-catenin stabilization. Cell Death Differ 25:1855-1869
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Li, Lei; Liu, Tongzheng; Li, Yunhui et al. (2018) The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene 37:2422-2431

Showing the most recent 10 out of 294 publications